REGENXBIO (NASDAQ:RGNX) reported Q2 2025 financial results and significant progress across its gene therapy pipeline. The company's cash position strengthened to $363.6 million, expected to fund operations into early 2027. Key developments include accelerated enrollment in the RGX-202 Duchenne muscular dystrophy pivotal trial, expected to complete by October 2025, with BLA submission planned for mid-2026.
The company reported Q2 2025 revenues of $21.4 million and a net loss of $70.9 million ($1.38 per share). Notable achievements include successful FDA inspections for clemidsogene lanparvovec (RGX-121) for MPS II, with a PDUFA date of November 9, 2025, and advancement of surabgene lomparvovec (sura-vec) for retinal diseases. The company secured a $250 million royalty agreement with Healthcare Royalty and amended its AbbVie collaboration with potential milestone payments of $200 million.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.